

In a Fast-Moving Industry, Stay Up-to-Date on the Happenings.
Here is a Glimpse of Our Favorite Stories from December 2022.

Funding Updates:

- 12.01.22 - Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca ([Endpts](#))
- 12.05.22 - Karyopharm Announces \$165 Million Private Placement ([PR](#))
- 12.06.22 - Entact Bio Emerges With \$81M to Play Matchmaker to Protein-Enhancing Drugs ([Medcitynews](#))
- 12.06.22 - Bouncing from major setback, Summit hands out \$500M cash for cancer drug – thanks to a loan from billionaire CEO ([Endpts](#))
- 12.06.22 - Baudax Bio Announces Closing of \$5 Million Public Offering ([PR](#))
- 12.06.22 - Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting ([PR](#))
- 12.06.22 - Entact Bio Launches with \$81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement ([PR](#))
- 12.07.22 - Apogee Therapeutics Launches with \$169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders ([PR](#))
- 12.08.22 - Eigen Therapeutics Emerges From Stealth With \$7M in Funding to Develop Therapies That Address Cancer Heterogeneity ([PR](#))
- 12.12.22 - CF Foundation Invests Up to \$4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective ([PR](#))
- 12.12.22 - Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company ([PR](#))
- 12.13.22 - Flagship Pioneering Unveils Montai Health to Treat and Prevent Chronic Disease Afflicting Two Billion People Worldwide ([PR](#))
- 12.14.22 - Alpha-9 Theranostics Announces Oversubscribed \$75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer ([PR](#))
- 12.15.22 - Enlaza Therapeutics Launches with \$61 Million Seed Financing to Advance the First Covalent Biologic Therapeutic Platform ([PR](#))
- 12.16.22 - Evelo Biosciences Announces \$45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt ([PR](#))
- 12.21.22 - Madrigal Pharmaceuticals Announces \$300+ Million in Financing Events to Advance Resmetirom Program ([PR](#))
- 12.23.22 - TERNS ANNOUNCES CLOSING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES ([PR](#))

Collaboration Updates:

- 12.08.22 - Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) ([PR](#))
- 12.12.22 - Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati ([fiercepharma](#))
- 12.13.22 - Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration ([PR](#))
- 12.14.22 - PrecisionLife Enters Multi-Target R&D Partnership with Ono Pharmaceutical ([ContractPharma](#))
- 12.15.22 - AbCellera, Abbvie Enter Strategic Antibody Alliance ([ContractPharma](#))
- 12.19.22 - Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration ([PR](#))
- 12.21.22 - Zymeworks sings to the tune of \$325M with Jazz opt-in for HER2 cancer drug ([Endpts](#))
- 12.23.22 - Mersana Inks Cancer Therapy Development Deal With Merck Germany ([Yahoofinance](#))
- 12.13.22 - Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics ([PR](#))
- 12.14.22 - Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq ([Endpts](#))
- 12.12.22 - Updated: Horizon's \$28B sale to Amgen was kicked off by Sanofi's interest ([Endpts](#))
- 12.14.22 - Novartis, busy with its restructuring, sells 5 eye drugs for up to \$175M ([Fiercepharma](#))
- 12.20.22 - KKR to Acquire Bushu Pharmaceuticals ([PR](#))
- 12.27.22 - Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics ([PR](#))

Clinical and Commercial Updates:

- 12.01.22 - Rigel Announces U.S. FDA Approval of REZLIDHIA™ for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation ([PR](#))
- 12.01.22 - Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder ([PR](#))
- 12.05.22 - Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology ([PR](#))
- 12.07.22 - With clear PhII win in IBD, Prometheus thwarts Pfizer comparisons as it follows Humira 'playbook' ([Endpts](#))
- 12.13.22 - Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors ([PR](#))
- 12.13.22 - Moderna vaccine succeeds in early-stage skin cancer study with Merck's Keytruda ([Biopharmadive](#))
- 12.15.22 - Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis ([PR](#))
- 12.15.22 - Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) ([PR](#))
- 12.19.22 - Ferring grabs first gene therapy approval in bladder cancer ([Pharmamanufacturing](#))
- 12.20.22 - Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval ([PR](#))
- 12.20.22 - Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer ([PR](#))
- 12.29.22 - Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults ([PR](#))

CDMO & Manufacturing Updates:

- 12.01.22 - August Bioservices Closes \$65M Series B ([PR](#))
- 12.08.22 - The CDMO space does not have the capacity to meet fill-finish demand, says Lonza ([Bioprocessintl](#))
- Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina ([LifeSciKnowledgeHub](#))
- 12.14.22 - Societal CDMO Announces Closing of \$35.6 Million Concurrent Public Offerings ([PR](#))
- 12.19.22 - Formulated Solutions to Acquire Newly Updated FDA Approved Drug Production Site ([ContractPharma](#))
- 12.20.22 - SCORPION BIOLOGICAL SERVICES BECOMES SCORPIUS BIOMANUFACTURING TO REFLECT EXPANSION ([PR](#))
- 01.02.22 - Polysciences Announces New Bioprocessing Brand, Kyfora Bio ([PR](#))
- 01.03.22 - Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, NY ([ContractPharma](#))
- 01.03.22 - GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation ([PR](#))

About Berke Search

The Berke Executive Search team is comprised of seasoned and engaged partners who lead our highly specialized firm with an unwavering commitment to excellence and integrity. With over two decades of experience conducting searches for C-Suite, Senior Commercial, Scientific Leadership, and specialized functional leadership disciplines, we have developed deep relationships and a large network of top talent. Our deep experience and expertise benefits clients by shrinking timelines and lowering talent acquisition costs. In addition, our nimble size (boutique) and highly selective client base virtually eliminate conflict of interest and off-limit issues; we execute only a select number of search pools to ensure our resources are maximized and enable superior success rates.

Visit us at Berkesearch.com